Corcept’s Lifyorli Shows 35% Survival Benefit in Platinum-Resistant Ovarian Cancer
Event summary
- Corcept presented new overall survival data from the ROSELLA trial at ASCO 2026, showing a 35% reduction in the risk of death for patients treated with Lifyorli plus nab-paclitaxel compared to nab-paclitaxel alone.
- Median overall survival was 16.0 months for the Lifyorli combination vs. 11.9 months for nab-paclitaxel alone.
- The trial enrolled 381 patients across the U.S., Europe, South Korea, Brazil, Argentina, Canada, and Australia.
- Lifyorli received FDA approval in March 2026 for platinum-resistant ovarian cancer and is included in the NCCN Guidelines as a preferred regimen.
The big picture
Corcept’s data positions Lifyorli as a potential new standard-of-care for platinum-resistant ovarian cancer, a disease with limited treatment options. The results underscore the role of cortisol modulation in oncology, potentially opening doors for Corcept’s pipeline in other tumor types. The company’s ability to leverage these findings will be critical as it seeks to expand its footprint in the oncology market.
What we're watching
- Clinical Expansion
- Whether Corcept can replicate these results in other cancer types, including platinum-sensitive ovarian, endometrial, cervical, pancreatic, and prostate cancers.
- Regulatory Momentum
- The pace at which Corcept advances its Marketing Authorisation Application with the EMA for relacorilant in platinum-resistant ovarian cancer.
- Market Adoption
- How quickly Lifyorli gains traction as a standard-of-care treatment, given its inclusion in the NCCN Guidelines and the unmet need in platinum-resistant ovarian cancer.